Table 2 The statistical association with molecular subtypes in different clinicopathologic characteristics across 498 tumor samples.
Parameter | 2 subtypes | 3 subtypes | 4 subtypes | 5 subtypes | 6 subtypes | 7 subtypes | 8 subtypes | 9 subtypes | Â |
|---|---|---|---|---|---|---|---|---|---|
Gleason score | 1.89E-02 | 1.07E-04 | 7.13E-09 | 5.91E-06 | 2.92E-07 | 4.84E-06 | 1.55E-06 | 8.97E-07 | KW Test |
Pathologic N stage | 1.85E-01 | 3.61E-02 | 4.16E-04 | 1.96E-03 | 1.32E-03 | 3.93E-03 | 4.77E-04 | 1.04E-03 | Chi-square |
Pathologic T stage | 1.77E-02 | 2.14E-02 | 2.60E-03 | 3.92E-02 | 2.47E-02 | 1.16E-02 | 1.14E-02 | 3.10E-02 | Chi-square |
Clinical T stage | 4.00E-01 | 5.27E-01 | 1.26E-01 | 1.76E-01 | 4.59E-02 | 6.79E-02 | 2.32E-02 | 1.19E-01 | Chi-square |
Positive lymph nodes number | 2.72E-01 | 3.85E-02 | 6.14E-05 | 3.38E-04 | 1.48E-04 | 1.05E-03 | 1.23E-04 | 3.59E-04 | KW Test |
PSA level | 9.14E-01 | 9.77E-01 | 5.50E-01 | 5.57E-01 | 4.79E-01 | 7.60E-01 | 8.40E-01 | 2.56E-01 | KW Test |
Time to Death | 9.79E-01 | 9.43E-01 | 5.65E-01 | 6.80E-01 | 6.15E-01 | 9.07E-01 | 7.38E-01 | 6.70E-01 | Logrank test |
